EN DE
Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation

Becton Dickinson and Company (BDX) fair value: what the stock is really worth

We calculate from audited financials what Becton Dickinson and Company is really worth. The fair value tells you whether the price is too high or too low, the quality score (0 to 100) how solid the business behind it is. 26 models, 37 quality factors, updated daily.

  1. Fair value above price? No
  2. Good quality? Yes
  3. Add to watchlist

Healthcare · US · ISIN US0758871091

BD Becton Dickinson and Company logo Broad data Sep 17, 2026

Becton Dickinson and Company

BDX · US

Stretched ValuationStrong overvaluation with only moderate quality.

!Fair value $100.46 · Strongly overvalued (−44%)
!Quality 63/100
✓Healthy Growth (revenue 5y +6.3 %/yr)
!Thin margins · 5.1% net margin (TTM)
✓Moderate debt · generates free cash flow
·2.31% dividend yield
✓Ranks above peers (9/15)
!Moderate moat 55/100
!Insider activity 40/100
!Weak on future: 26 out of 100
!Weak on past: 27 out of 100
Watch Becton Dickinson and Company for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card. Watch for free Pro now: $1 first month

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$210.15 $125.97 Fair Value $100.46 Jun 2021 Sep 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 17, 2026.

How to read this chart

60‑month range $125.97 – $210.15 · fair‑value band $64.79 – $155.37 · the $180.94 price screens above the $100.46 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 17, 2026.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide.

Show more

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. It operates through Medical Essentials, Connected Care, BioPharma Systems, Interventional and Life Sciences segments. It provides peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular access technology, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication safety and infusion therapy delivery systems, medication compounding workflow system, automated medication dispensing and supply management systems, informatics and analytics and pharmacy automation system, and medication inventory optimization and tracking system; hemodynamic monitoring system; and prefillable drug delivery systems. It also offers specimen and blood collection products; automated blood and tuberculosis culturing, molecular testing, and microorganism identification and drug susceptibility, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent system, and solution for single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. It provides hernia and soft tissue repair, biological and bioresorbable graft, biosurgery, and other surgical products; surgical infection prevention, peripheral intervention, and urology and critical care products. The company has a strategic collaboration with ChemoGLO for the advancement of hazardous drug contamination testing in health care

Stock analysis

Becton Dickinson and Company (BDX) currently trades at $180.94, while our model-based Fair Value estimate is $100.46, implying the stock looks roughly 80.1% overvalued today.

Show more

Valuation

Bull case: the Growth Earnings group reads highest at a median of $119.52 per share, and 2 of the 26 models we run sit above the $180.94 price.

Bear case: the Economic Profit group reads lowest at $32.70, and 24 of the 26 models stay below the price. Evidence for this calculation is high.

Scenario range: $64.79 (bear) to $155.37 (bull), the price of $180.94 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 63/100 (solid quality), in the Healthcare sector.

Healthy Growth: Revenue growth appears healthy and is supported by profitability and cash-flow quality.

Becton Dickinson and Company reported revenue of $21.8B in FY2025 versus $19.1B in FY2021, a compound +3.4%/yr. Reported net income was $1.7B in FY2025, compounding −5.4%/yr from FY2021.

Key figures

Market cap $52.0B · P/E ratio 31.6 · P/S ratio 2.43 · EPS (TTM) $5.72 · Dividend yield 2.3% · Net margin 7.7% · Return on equity 6.7% · Return on assets (EBIT) 4.3%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 58 out of 100 (medium confidence).

What moves the price

The last reported earnings sit well below what analysts expect (earnings in transition, for example after write-downs or an earnings dip); whether the stock is cheap or expensive hinges on the expected recovery actually arriving. Read the fair value with that caveat.

The share trades about 3% below its 52-week high and 44% above its 52-week low, currently above its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −41% fair-value upside, at −44%, BDX screens richer than that median.

Fair Value models

Bear $64.79 Fair Value $100.46 Bull $155.37
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Based on fiscal year 2025 figures (about 12 months old). Earnings retained since then ($1.51 per share) are deliberately not added. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Highest evidence
FCF DCF $50.15 $113.87 $212.04 76
Residual Income $74.56 $78.35 $82.24 76
Growth DCF $51.87 $107.92 $188.79 75
All 26 models by family
DCF Models
FCF DCF $50.15 $113.87 $212.04 76
Owner Earnings $79.68 $160.33 $284.61 73
5Y Revenue Exit $30.79 $82.59 $148.36 68
5Y EBITDA Exit $89.60 $193.40 $315.42 72
5Y P/E Exit $36.19 $92.77 $152.06 68
10Y Revenue Exit $34.11 $83.25 $148.87 63
10Y EBITDA Exit $74.32 $160.49 $277.24 65
10Y P/E Exit $40.18 $90.35 $151.71 61
Earnings-Based
Graham-Dodd $41.41 $133.38 $177.99 64
Lynch FV $29.63 $42.32 $55.02 61
PEG = 1.0 $29.63 $42.32 $55.02 57
EPV $19.33 $32.70 $44.39 72
Dividend Discount
Gordon GGM $39.85 $82.87 $131.46 66
DDM Multi-Stage $39.85 $66.93 $86.97 66
Multiples
P/E Multiple $100.48 $133.98 $167.47 63
P/S Multiple $77.65 $103.53 $129.41 58
P/B Multiple $77.65 $103.53 $129.41 55
EV/EBIT $58.43 $98.19 $137.96 64
EV/EBITDA $131.20 $195.22 $259.24 66
EV/Revenue $24.28 $60.77 $97.26 50
Asset-Based
NCAV (Graham) $46.07 $61.74 $92.15 54
Growth DCF
Growth DCF $51.87 $107.92 $188.79 75
Rev-Margin DCF $30.79 $83.02 $143.79 69
Economic Profit
Residual Income $74.56 $78.35 $82.24 76
ROIC Compounder $19.33 $32.70 $44.39 70
Growth Earnings
Growth-Adj P/E $83.66 $119.52 $155.37 67

Open the full fair value analysis →

Notify me when BDX reaches fair value

Put BDX on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Quality Score breakdown

Overall quality 63/100

Of which business quality 59 · Market factors (momentum, volatility) 77

Profitability 32
Margins and returns on capital today
Quality Growth 51
Are margins and returns improving?
Cashflow 72
Earnings quality: real cash, not paper profit
Fin. Strength 41
Balance sheet, leverage, solvency risk
Investment 95
Disciplined investing over empire-building
Low Volatility 88
Calm price path (market factor)
Momentum 68
Price trend over the last 3–12 months (market factor)
52W Momentum 77
Distance to the 52-week high (market factor)
Net Issuance 89
Share count: buybacks or dilution?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 72/100
Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Revenue growth 1 year
+8.2%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+5.0%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+6.3%
Revenue growth 40 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+7.7%
What shareholders gained per year (last 5 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate.
+7.7%
Earnings growth per share plus dividend.
Earnings per share, growth per year+5.4%
Dividend (yield on the price)2.3%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.5% vs 3%, steady
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.6% → 12%

Growth Forecast

A lot of optimism in the price
The price assumes more growth than the company has delivered so far and more than analysts expect.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+9.9%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect ⓘAnalysts publish sales forecasts for the next two fiscal years. For the years after that, growth slows evenly to 2 % a year by year ten (2 % is the long-run rate our models use). Projected years are marked as such.
−0.6%
Yearly sales growth analysts expect, extended to five years.
Forecast 2026 (sales)−12.1%
Forecast 2027 (sales)+2.6%
Projected 2028 (sales)+2.6%
Projected 2029 (sales)+2.5%
Projected 2030 (sales)+2.4%

BDX screens 80% overvalued. Compare with Intuitive Surgical, Inc →

Recent news

News mood ⓘNews mood, the average tone of recent news (100 articles), rated against how stocks are usually covered. 🚀 Hype = unusually upbeat · 🙂 Positive = above average · 😐 Neutral = typical · 🙁 Negative = below average · 😨 Very negative = unusually downbeat. It reflects the tone of coverage, not our valuation. Hype
Recent news coverage is unusually upbeat, far more positive than stocks are typically covered.

Compare Becton Dickinson and Company with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Instruments & Supplies · 200 stocks

Beats the industry median on 9/15 measures
Overall it ranks above its industry peers.
Valuation
Quality Score 63 · Above median
Fair Value upside −46% · Below median
Profitability
Return on equity (TTM) 7% · Above median
Return on assets 4% · Above median
Net margin (TTM) 5% · Below median
Operating margin (TTM) 15% · Above median
Growth and dividend
Revenue growth 5% · Below median
Dividend yield (TTM) 2.3% · Above median
Balance sheet
Debt / equity 0.69× · Highest 25%

Valuation Multiplesvs Medical Instruments & Supplies median · lower = cheaper

P/E (TTM) 31.6× · Pricier than median
P/B 1.63× · Cheaper than median
P/S (TTM) 1.87× · Cheaper than median
P/FCF 15.5× · Pricier than median
EV/EBITDA 9.5× · Cheaper than median
PEG 1.11× · Cheaper than median

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 15
FUTURE (revenue growth)26 · sector 27
PAST (return on equity)27 · sector 25
HEALTH (low debt)65 · sector 96
DIVIDEND (yield)46 · sector 32

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Medical Instruments & Supplies stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value
Intuitive Surgical, Inc ISRG $377.16 $350.02 −7%
EssilorLuxottica Société anonyme EL €145.10 €159.61 +10%
Medline Inc MDLN $32.11 $11.65 −64%
Alcon Inc ALC $67.76 $39.78 −41%
ResMed Inc RMD A$31.90 A$35.09 +10%
West Pharmaceutical Services, Inc WST $362.01 $137.28 −62%
Sartorius Stedim Biotech S.A DIM €196.10 €48.88 −75%
Straumann Holding STMN CHF 94.66 CHF 45.50 −52%
Sartorius Aktiengesellschaft SRT3 €248.70 €42.05 −83%
Coloplast A/S COLOB kr 420.10 kr 382.22 −9%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Calculator with industry benchmark Peter Lynch Fair Value Formula &…Calculator with industry benchmark
Run the numbers yourself: free valuation calculators
DCF CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorFama-French ModelIntrinsic Value
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Becton Dickinson and Company · Fair Value
$100.46 −80%Fair Value
Calculator →

Cite: Fair Value Calculator (2026). "Becton Dickinson and Company Fair Value". https://www.fairvalue-calculator.com/stock/BDX

Frequently asked questions

Is Becton Dickinson and Company (BDX) overvalued or undervalued?
As of Sep 17, 2026, our model estimates a fair value of $100.46 versus a price of $180.94, about −44% upside (overvalued).
What is the fair value of BDX?
Our model-based fair value for Becton Dickinson and Company is $100.46 (as of Sep 17, 2026), built from audited fundamentals. The current price: $180.94.
What is the quality score of BDX?
Becton Dickinson and Company has a Quality Score of 63/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Becton Dickinson and Company (BDX)?
Our model-based price target is the fair value of $100.46 (as of Sep 17, 2026) from 26 valuation models. Cautious scenario $64.79, optimistic scenario $155.37. It is a calculation from audited fundamentals, not an analyst target.
What is the Becton Dickinson and Company stock forecast for 2026?
Our models put fair value at $100.46, about −44% upside versus a price of $180.94 (overvalued). Cautious scenario $64.79, optimistic scenario $155.37. The calculation is refreshed regularly with new filings.
What is the revenue of Becton Dickinson and Company (BDX)?
Becton Dickinson and Company reported trailing-twelve-month revenue of about $22.2B (latest available figure, as of Sep 17, 2026).
Does Becton Dickinson and Company pay a dividend?
Becton Dickinson and Company currently shows a dividend yield of about 2.31% relative to its recent price (as of Sep 17, 2026).
What growth is priced into Becton Dickinson and Company (BDX)?
For today's price to be fair in a discounted-cash-flow model, Becton Dickinson and Company would have to grow free cash flow by +9.9 % per year for five years (discount rate 8.1 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +6.3 % per year. As of Sep 17, 2026.
What discount rate (WACC) does the fair value of BDX use?
Our models discount Becton Dickinson and Company at 8.1 %: a base by market capitalisation (large), damped by beta 0.27, country premium for USA. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Becton Dickinson and Company that is +9.9 % per year a year over ten years, using the same discount rate (8.1 %) and the same formula as our fair value.
How much growth has Becton Dickinson and Company (BDX) delivered so far?
Over the past 5 years revenue at Becton Dickinson and Company grew +6.3 % a year. The price currently implies +9.9 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Becton Dickinson and Company (BDX) growing?
The median revenue growth in the sector is +4.3 % a year. That is the yardstick for the growth priced into Becton Dickinson and Company (+9.9 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Becton Dickinson and Company (BDX)?
The free-cash-flow yield on the price is 5.14 %: that much free cash flow Becton Dickinson and Company produces per unit of market value. When it exceeds the discount rate of our models (8.1 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Becton Dickinson and Company (BDX)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Becton Dickinson and Company it is $100.46 per share (as of Sep 17, 2026), against a price of $180.94. It is the blended result of 26 valuation models (cash flow, earnings, asset, dividend).
Is Becton Dickinson and Company stock overvalued or undervalued in 2026?
As of Sep 17, 2026, BDX trades above its calculated fair value: price $180.94, fair value $100.46, a gap of about −44% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of BDX?
No. The price is what the market pays today ($180.94); the fair value is what the company's own numbers justify ($100.46). For Becton Dickinson and Company the two are $80.48 per share apart. That gap is exactly why we show both numbers side by side.
How much is Becton Dickinson and Company worth?
The market values Becton Dickinson and Company at about $52.0B (market capitalisation, as of Sep 17, 2026). Per share that is $180.94; our models calculate a fair value of $100.46 per share.
What do the bullish and bearish scenarios say about BDX?
Our models span a range for Becton Dickinson and Company: cautious scenario $64.79, base $100.46, optimistic $155.37 per share (as of Sep 17, 2026, price $180.94). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of BDX?
Becton Dickinson and Company trades at a price-to-earnings ratio of 31.6 (as of Sep 17, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of $100.46 is built from several models across several years. Other multiples: PEG 1.1, P/B 1.6, P/S 1.9, EV/EBITDA 9.5.
What is the PEG ratio of BDX?
The PEG ratio of Becton Dickinson and Company is 1.11 (P/E divided by earnings growth, as of Sep 17, 2026). That is above 1, so the growth is already paid for in the price.
How solid is the balance sheet of Becton Dickinson and Company (BDX)?
Balance-sheet figures for Becton Dickinson and Company (as of Sep 17, 2026): return on equity 6.7%, debt of 0.69 per unit of equity. They feed the Quality Score of 63/100, which measures business quality independently of the share price.
How far is BDX from its 52-week high?
Becton Dickinson and Company trades at $180.94, about 3% below its 52-week high of $186.16 and 44% above the low of $126.09 (as of Sep 17, 2026). Distance from the high says nothing about value: that is what the fair value of $100.46 is for.
Which stocks are comparable to Becton Dickinson and Company?
From the same area (Healthcare) we also value Intuitive Surgical, Inc, EssilorLuxottica Société anonyme, Medline Inc, Alcon Inc, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Becton Dickinson and Company stock attractive at the current price?
The data as of Sep 17, 2026: price $180.94, calculated fair value $100.46 (−44%), Quality Score 63/100, from 26 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of BDX calculated?
We run Becton Dickinson and Company through 26 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $100.46, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 16.1 % above its aggregate fair value. Becton Dickinson and Company itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Becton Dickinson and Company (BDX)?
The closing price on Sep 18, 2026 was $180.94. Our model-based fair value is $100.46, about −44% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Becton Dickinson and Company right now?
The price sits above even our optimistic bull case ($155.37). The favourable scenario is already priced in. Solid but not exceptional quality (63/100) and above fair value, neither a clear bargain nor a standout compounder. A fairly wide model range ($64.79 to $155.37) leaves room in how you read the outcome.
Where does the earnings growth of Becton Dickinson and Company (BDX) come from?
Earnings per share at Becton Dickinson and Company grew +2.3 % a year from 2014 to 2025. Broken into its drivers: revenue per share +3.9 %, EBIT margin −1.5 %, tax rate +0.4 %, residual (interest, one-offs) −0.5 %. The four rates multiply to the earnings growth rate, they do not add up. Start and end are three-year averages so a single exceptional year does not distort the result.

Key figures of Becton Dickinson and Company

How large is the market capitalisation of Becton Dickinson and Company (BDX)?
The market capitalisation of Becton Dickinson and Company is $52.0B. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Becton Dickinson and Company (BDX)?
The price-to-sales ratio of Becton Dickinson and Company is 2.43 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Becton Dickinson and Company (BDX)?
Earnings per share at Becton Dickinson and Company are $5.72 (price ÷ EPS = P/E 31.6). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Becton Dickinson and Company (BDX)?
The dividend yield of Becton Dickinson and Company is 2.3% (payout 73.1%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Becton Dickinson and Company (BDX)?
The net margin of Becton Dickinson and Company is 7.7% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Becton Dickinson and Company (BDX)?
The return on equity (ROE) of Becton Dickinson and Company is 6.7% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Becton Dickinson and Company (BDX)?
On an EBIT basis the return on assets of Becton Dickinson and Company is 4.3% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Becton Dickinson and Company (BDX)?
The operating margin of Becton Dickinson and Company is 14.7% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Becton Dickinson and Company (BDX)?
Revenue at Becton Dickinson and Company is growing +5.2% versus a year earlier (3y avg +5.0%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Becton Dickinson and Company (BDX)?
Earnings per share at Becton Dickinson and Company are growing +28.6% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does Becton Dickinson and Company (BDX) carry?
The net debt of Becton Dickinson and Company is $18.3B (fiscal year 2025, ≈ 6.9 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch Becton Dickinson and Company in the live analysis

One click puts Becton Dickinson and Company on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.